FDA grants orphan drug designation for neuroblastoma vaccine

OPACC
Oct 6, 2014
1 min read

The U.S. Food and Drug Administration (FDA) granted orphan drug designation for a neuroblastoma vaccine from MabVax Therapeutics, providing development incentive with market exclusivity of the novel treatment for children with this deadly childhood cancer.

Comments

New study: Siblings of children with cancer frequently experience serious suffering

Radiation From Medical Scans May Cause Thousands Of Childhood Cancers, Study Says

Survey: Childhood Cancer Survivors Seek More Support from Healthcare Providers, Peers, and Policymakers

Understanding genomes helps identify kids more likely to develop second cancers

Combo Appears Safe, Effective in High-Risk Intraocular Retinoblastoma

Cancer Vaccine Could Prevent Neuroblastoma From Returning After Antibody Treatment

New Approach for Smarter, Safer Cancer Treatment

Abnormal fusion protein drives childhood brain tumor through condensate formation

Potential new treatment strategy for high-risk neuroblastoma

Targeting a sugar metabolism pathway offers hope for treating rare and aggressive childhood cancer

Recent Posts